OCHA and the United Nations

June 16, 2009

The stage for international power struggles and as a constant source of opprobrium by right wing conservatives. It provides the backdrop for clashes that receive heavy coverage in the media. Virtually ignored by the press, however, are its myriad humanitarian and scientific agencies.

Read the full article

Overcoming Protein Production Hurdles

June 3, 2009

Recombinant antibodies have emerged as dominant players in the biopharma industry despite the copious quantities required for treatment. Although nonantibody biologics are typically produced at much smaller scale, are less complex, and have limited secondary modifications, their production is also fraught with challenges.

Read the full article

About Us

Newport Biotechnology Consultants, founded in 2005, originally was aimed at providing writing expertise in the life sciences industry, with a specialization in molecular immunology. I drew upon my academic and industrial background to cover new developments and technologies in antibody therapies and related areas of biotechnology. These reviews were published in a number of trade journals, especially articles in Genetic Engineering and Biotechnology News (see articles). More recently I have expanded my writing into other fields, including emergency management, drug discovery, bioprocessing, environmental and sustainable technologies, micro- and nanotechnology and many other areas. I also am involved in regulatory issues. I am Chair of the Meridian Bioscience Institutional Biosafety Committee, and I am a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee (see consulting services). Both IBCs review research protocols dealing with the use of recombinant DNA. Finally, I have consulted for a number of companies on laboratory design, business plan evaluation and regulatory questions.

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin